Given the frequency of epidermal growth factor receptor (EGFR) expression on NPC, in 73.3-84.1% of cases (17–20), several studies evaluated treatment with anti-EGFR therapy in collaboration with CRT for LA-NPC (21–23) and with chemotherapy for R/M NPC (15, 24–26), and reported promising clinical efficacy against these diseases. The gene discussed is EGFR; the disease is nasopharyngeal carcinoma.